Transgene a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and ProBioGen, a CDMO in biologics, vaccines and viral vectors have entered a licensing agreement to advance manufacturing capabilities for personalised cancer vaccines using ProBioGen’s
ProBioGen, the Berlin-based Contract Development & Manufacturing Organisation (CDMO) has announced a significant partnership with DIOSynVax Ltd to manufacture DIOS-HFVac3, a trivalent hemorrhagic fever (HF) vaccine targeting diseases caused by Ebola, Marburg, and Lassa viruses. The novel vaccine, developed in
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
